Medical Biochemistry Laboratory, Edirne Public Health Institution, Turkey.
Med Hypotheses. 2021 Jun;151:110590. doi: 10.1016/j.mehy.2021.110590. Epub 2021 Mar 29.
Coronavirus disease 2019 (COVID-19) is an inflammatory process with complex pathophysiology and by affecting the cardiovascular system directly or indirectly that causes life threatening cardiac injuries. Therefore, clarifying the effects of this infection on the cardiovascular system is of importance in terms of the clinical course of the disease. The increases in cardiac and inflammatory biomarkers in COVID-19 have been associated with poor prognosis and mortality. However, there are no specific laboratory markers yet to assess the severity of the disease. In this context, the combination of available biomarkers is needed to better define the clinical course of this disease. Carbohydrate antigen 125 (CA-125) has become a remarkable marker in recent years as a result of the correlation of increasing levels in cardiovascular diseases with clinical, hemodynamic, echocardiographic parameters and its relation with mortality or re-hospitalization due to heart failure. These findings suggest that CA-125 might be useful biomarker to identify the damage mechanisms of COVID-19, monitoring the prognosis of the disease and the course of the treatment.
新型冠状病毒病（COVID-19）是一种炎症过程，具有复杂的病理生理学，通过直接或间接影响心血管系统导致危及生命的心脏损伤。因此，明确这种感染对心血管系统的影响对于疾病的临床过程非常重要。COVID-19 中心脏和炎症生物标志物的增加与不良预后和死亡率相关。然而，目前还没有特定的实验室标志物来评估疾病的严重程度。在这种情况下，需要结合现有生物标志物来更好地定义这种疾病的临床过程。糖链抗原 125（CA-125）近年来成为一个显著的标志物，因为它在心血管疾病中的水平升高与临床、血液动力学、超声心动图参数相关，并与心力衰竭导致的死亡率或再住院相关。这些发现表明，CA-125 可能是一种有用的生物标志物，可用于识别 COVID-19 的损伤机制，监测疾病的预后和治疗过程。
